Peptides News and Research

RSS

Anesthesia can increase behavioral changes, risk of developing Alzheimer's disease

The use of repetitive anesthesia with isoflurane (one of the most common anesthetics by inhalation) increases the risk of developing changes similar to those observed in AD brains in mice with mutations of the amyloid precursor protein (APP). This is the main conclusion of Spanish researchers coordinated by Doctors Maria -ngeles Mena and Justo Garc-a de Y-benes, from CIBERNED (Centro de Investigaci-n Biom-dica en Red de Enfermedades Neurodegenerativas).

25 Mar 2010

NIH grant for study on impact of gastric bypass surgery on Type II diabetes patients

Gastric bypass surgery, thought of by many as the last hope of morbidly obese people for losing weight, has many other benefits researchers are only beginning to understand.

25 Mar 2010

Bariatric surgery may delay onset of type 2 diabetes, says study

A team of researchers, led by a UC Davis veterinary endocrinologist, has shown for the first time that a surgical procedure in rats that is similar to bariatric surgery in humans can delay the onset of type 2 diabetes.

25 Mar 2010

PPD introduces comprehensive laboratory services for vaccine and biologic drug development

PPD, Inc. (Nasdaq: PPDI) today announced it is launching the PPD Vaccines & Biologics Center of Excellence, a first-in-kind comprehensive network of integrated, world-class laboratory services focused specifically on vaccine and biologic drug development.

24 Mar 2010

Genetic accident in sea provides new insight into diabetes: New research

A genetic accident in the sea more than 500 million years ago has provided new insight into diabetes, according to research from Queen Mary, University of London.

23 Mar 2010

NexACT technology demonstrates ability to deliver Taxol subcutaneously

NexMed, Inc., a specialty CRO and a developer of products based on the NexACT® technology, today announced that pre-clinical results from the research and development group at its Bio-Quant subsidiary have successfully demonstrated the ability of the NexACT technology to deliver insulin and other large molecule drugs such as Taxol subcutaneously, in a depot-like fashion (or slow release) over a 24 hour period from a single injection.

18 Mar 2010

OriGene Technologies to build TrueMAB monoclonal antibody collection with $16M Series B financing funds

OriGene Technologies, Inc., a leading gene-centric life sciences company, announced the completion of a $16 million Series B financing led by IDG-Accel, SBI & TH Venture Capital Enterprise, and Zero2IPO. OriGene's previous investors Morningside Venture Investments and President International Development Corp. (PIDC) also participated in this round. The proceeds from the funding will be used to continue to build OriGene's TrueMAB™ monoclonal antibody collection.

18 Mar 2010

Expectant mothers’ spatial memory ability reduces during later stages of pregnancy

New research has found that pregnant women's ability to remember the position of objects previously seen is reduced as pregnancy progresses. These findings will be presented this week at the annual Society for Endocrinology BES conference in Manchester.

18 Mar 2010

Agilent Technologies introduces new ion exchange and size exclusion columns for analysis of bio-molecules

Agilent Technologies Inc. today announced the availability of new ion exchange and size exclusion columns specifically designed for the analysis of bio-molecules including monoclonal antibodies, recombinant proteins, peptides, vaccine products and DNA/RNA. The columns provide robust, reproducible and high-resolution solutions for biopharmaceutical manufacturers to effectively monitor the safety, efficacy and stability of their products.

17 Mar 2010

Compugen announces validation of IDD discovery platform for identification of cell penetrating peptides

Compugen Ltd. announced today the development and validation of its Intracellular Drug Delivery (IDD) discovery platform for identification of cell penetrating peptides. Compugen also announced that as part of the validation process for the new platform, more than twenty novel peptides, predicted and selected in silico, demonstrated the predicted cell penetrating properties in initial experimental validation studies.

17 Mar 2010

Test tube studies offer new hope for Alzheimer’s patients

A team of scientists from SLU in Uppsala and University of Cambridge have discovered a molecule that can prevent a toxic protein involved Alzheimer's disease from building up in the brain.

17 Mar 2010

Kinexus Bioinformatics launches new peptide synthesis facility

Kinexus Bioinformatics Corporation, a world leader in functional proteomics research, announced the launch of a new peptide synthesis facility to provide researchers with the latest in peptide array technologies. These new services will facilitate and expedite access to peptide platforms for innovative approaches to proteomic research and discovery.

16 Mar 2010

Workings of IGFs on muscle cells

The muscle-building abilities of hormones known as insulin-like growth factors (IGFs) are legendary. Just do an online search and you'll find not only scientific papers discussing the effects of IGFs on the cells that give rise to muscle tissue, but also scores of ads touting the purported benefits of IGF supplements for bodybuilding.

16 Mar 2010

Rhythm Pharmaceuticals completes $21M Series A equity financing

Rhythm Pharmaceuticals, a biotechnology company developing peptide therapeutics for metabolic diseases, announced today that it has completed the first close on its Series A equity financing of $21 million. The financing was led by MPM Capital and New Enterprise Associates. The funds will be used to develop products licensed from Ipsen.

15 Mar 2010

NDA for BYDUREON: FDA issues complete response letter

Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. today announced that the U.S. Food and Drug Administration has issued a complete response letter regarding the New Drug Application for BYDUREON™ (exenatide for extended-release injectable suspension).

15 Mar 2010

Ipsen grants Rhythm exclusive global license for melanocortin and ghrelin programs

Ipsen, a global biotechnology specialty care group, and Rhythm Pharmaceuticals, a biotechnology company developing peptide therapeutics for metabolic diseases, announced today that they have concluded a license agreement for Ipsen’s proprietary peptide therapeutics targeting obesity, metabolic diseases, and gastrointestinal disorders.

12 Mar 2010

Helix BioMedix enters into distribution agreement with RubyDerm Bio

Helix BioMedix, Inc., a developer of bioactive peptides, announced that the Company entered into an agreement with RubyDerm Bio, Inc. under which RubyDerm will assume responsibility, on an exclusive basis, for the distribution of certain of Helix BioMedix’s branded prestige skin care products to spas, beauty stores, hospitals, clinics, physicians, and consumers in South Korea, China and Japan.

11 Mar 2010

Helix BioMedix announces additional funding of $2.9M through convertible promissory notes

Helix BioMedix, Inc., a developer of bioactive peptides, announced additional funding in the amount of $2.9 million through convertible promissory notes. The company also announced the addition of Lawrence Blake Jones to its board of directors.

10 Mar 2010

Envy Medical launches new Lumixyl Brightening System for treating hyperpigmentation

Envy Medical, Inc., introduces the new Lumixyl™ Brightening System, a revolutionary multi-faceted approach to effectively treat hyperpigmentation without irritation or other side effects associated with prescription Hydroquinone or retinoids. This professional skincare system introduction builds on the success of the Lumixyl Topical Brightening Creme introduced in 2009.

9 Mar 2010

Three researchers to be honored with SBS Award for achievement in biomolecular sciences and lead discovery

The Society for Biomolecular Sciences will honor three researchers for their substantial contributions to the field of drug discovery. Each recipient will accept their award and speak at the SBS 16th Annual Conference & Exhibition in Phoenix, Arizona, April 11-15, 2010.

9 Mar 2010

Peptides News and Research

Anesthesia can increase behavioral changes, risk of developing Alzheimer's disease

NIH grant for study on impact of gastric bypass surgery on Type II diabetes patients

Bariatric surgery may delay onset of type 2 diabetes, says study

PPD introduces comprehensive laboratory services for vaccine and biologic drug development

Genetic accident in sea provides new insight into diabetes: New research

NexACT technology demonstrates ability to deliver Taxol subcutaneously

OriGene Technologies to build TrueMAB monoclonal antibody collection with $16M Series B financing funds

Expectant mothers’ spatial memory ability reduces during later stages of pregnancy

Agilent Technologies introduces new ion exchange and size exclusion columns for analysis of bio-molecules

Compugen announces validation of IDD discovery platform for identification of cell penetrating peptides

Test tube studies offer new hope for Alzheimer’s patients

Kinexus Bioinformatics launches new peptide synthesis facility

Workings of IGFs on muscle cells

Rhythm Pharmaceuticals completes $21M Series A equity financing

NDA for BYDUREON: FDA issues complete response letter

Ipsen grants Rhythm exclusive global license for melanocortin and ghrelin programs

Helix BioMedix enters into distribution agreement with RubyDerm Bio

Helix BioMedix announces additional funding of $2.9M through convertible promissory notes

Envy Medical launches new Lumixyl Brightening System for treating hyperpigmentation

Three researchers to be honored with SBS Award for achievement in biomolecular sciences and lead discovery

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News